Back to Search
Start Over
A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
- Source :
- Journal of Clinical Oncology. 36:TPS3110-TPS3110
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- TPS3110Background: Advanced hepatocellular carcinoma (HCC) accounts for 70% of diagnosed HCC. Tislelizumab (also known as BGB-A317) is a humanized, IgG4 monoclonal antibody with high affinity and b...
- Subjects :
- Oncology
Sorafenib
Cancer Research
medicine.medical_specialty
business.industry
medicine.drug_class
Anti pd 1
Monoclonal antibody
medicine.disease
digestive system diseases
First line treatment
03 medical and health sciences
0302 clinical medicine
Multicenter study
030220 oncology & carcinogenesis
Internal medicine
Hepatocellular carcinoma
medicine
030211 gastroenterology & hepatology
In patient
Open label
business
neoplasms
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........3a32932a1042e957551810b53f7e3f0d